Chronic Liver Disease Clinical Trial
Official title:
Nutritional Assessment Tool and Nutritional Intervention in Childhood Chronic Liver Disease
Children (Exclusively breast fed: 6mo - 3yrs, and who are not exclusively breast fed 3mo to 3
yrs) with infantile cholestasis syndrome will be randomized to either recieve indigenously
prepared oral nutritional supplement (energy dense supplement appox. 2 kcal/mL, prepared from
locally available, affordable, socially acceptable food items - milk, sugar, edible coconut
oil, egg and custard powder as base) in addition to standard nutritional counseling by a
trained dietician (Group A). The control group (Group B) in comparison will receive standard
nutritional counseling from a trained dietician but will not receive any additional
nutritional supplement. All the children will be followed up at 1 month, 3 months, 6 months,
9 months and 1 year after inclusion. Clinical, nutritional assessment and laboratory data
will be collected at each visit. Additionally IL-6 levels will be done at each visit in
children of both arms of the intervention group.
The outcomes of interest will be growth and improvement of nutritional status parameters,
hepatic morbidity (ascites, gastrointestinal bleeding, encephalopathy, {SBP (Spontaneous
Bacterial Peritonitis), HRS (Hepatorenal Syndrome), etc and outcome (improvement, death or
Liver Transplantation}.
All children will receive individualized standard treatment for infantile cholestasis
syndrome including vitamin supplements/endotherapy/ beta blockers/ prophylaxis for SBP
(Spontaneous Bacterial Peritonitis)/cholangitis (to at risk children) and drug therapy
wherever indicated (steroids/ copper chelation/ UDCA).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03704792 -
Validation of the Second Generation of the Controlled Attenuation Parameter (CAP) Using the MRI-PDFF as Reference
|
N/A | |
| Terminated |
NCT02949375 -
Trial to Examine the Effect of Two Doses of GRI-0621 in Patients With Chronic Liver Disease
|
Phase 2 | |
| Active, not recruiting |
NCT01205074 -
¹³C-Methacetin Breath Test (MBT) Methodology Study
|
Phase 2/Phase 3 | |
| Completed |
NCT00756171 -
Colesevelam Versus Placebo in Cholestatic Pruritus
|
Phase 2/Phase 3 | |
| Completed |
NCT01195181 -
Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.
|
Phase 4 | |
| Completed |
NCT05044663 -
Liver and Splenic Stiffness in Predicting Esophageal Varices Needing Treatment in NASH Related Compensated Advanced Chronic Liver Disease.
|
||
| Recruiting |
NCT04588077 -
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
|
Phase 4 | |
| Recruiting |
NCT04802954 -
Risk Stratification of Hepatocarcinogenesis Using a Deep Learning Based Clinical, Biological and Ultrasound Model in High-risk Patients
|
N/A | |
| Recruiting |
NCT04622449 -
Etiopathogenesis of Anemia in Chronic Liver Disease
|
||
| Enrolling by invitation |
NCT05836246 -
The Development of Quantitative Ultrasound Imaging Software Platform
|
||
| Completed |
NCT03087344 -
Postprandial Liver and Spleen Stiffness Measurements in the Noninvasive Diagnosis of Cirrhosis
|
N/A | |
| Completed |
NCT04751045 -
Comparison and Outcomes of Endoscopic Ultrasound Liver Biopsies Versus Percutaneous Liver Biopsies
|
N/A | |
| Not yet recruiting |
NCT04526548 -
A Diagnostic Study on Patients With Drug-induced Liver Injury
|
||
| Withdrawn |
NCT02899325 -
FDGal PET/CT to Detect Hepatocellular Carcinoma
|
||
| Terminated |
NCT02530567 -
Non-invasive Evaluation of Portal Pressure by MRI
|
N/A | |
| Suspended |
NCT02650011 -
Clinical Features and Natural History of Acute-on-Chronic Liver Failure in Korean Patients With Chronic Liver Disease
|
||
| Completed |
NCT01851252 -
MBT Versus HVPG in Identifying Responders to Portal Hypertension Therapy
|
Phase 1 | |
| Terminated |
NCT01756690 -
Predicting Lung Injury From Transfusion in Patients With Liver Disease
|
N/A | |
| Completed |
NCT01600105 -
Detection of Liver Fibrosis With Magnetic Resonance Imaging (MRI)
|
Phase 4 | |
| Completed |
NCT01008293 -
Effect of Probiotics in Treatment of Minimal Hepatic Encephalopathy (MHE) and Health Related Quality of Life
|
Phase 2/Phase 3 |